Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy

Hepatocellular carcinoma (HCC) is one of the deadliest cancers due to its complexities, reoccurrence after surgical resection, metastasis and heterogeneity. In addition to sorafenib and lenvatinib for the treatment of HCC approved by FDA, various strategies including transarterial chemoembolization,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yongbing, Ma, Wen, Yang, Yuanyuan, He, Mengxue, Li, Aimin, Bai, Lei, Yu, Bin, Yu, Zhiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shenyang Pharmaceutical University 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7032247/
https://www.ncbi.nlm.nih.gov/pubmed/32104485
http://dx.doi.org/10.1016/j.ajps.2019.04.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7032247/
https://www.ncbi.nlm.nih.gov/pubmed/32104485
http://dx.doi.org/10.1016/j.ajps.2019.04.005

Ejemplares similares